Abstract
Background:
Regional citrate anticoagulant (RCA) is recommended as the preferred anticoagulant regimen for continuous renal replacement therapy (CRRT) in adults; however, it is rarely reported in neonates due to concerns associated with their immature liver. Few studies have reported on the use of RCA to evaluate the safety and efficacy of RCA-CRRT in neonates.
Method:
In this retrospective observational study, we reviewed the clinical records of neonates who underwent RCA-CRRT at our pediatric intensive care unit between September 2015 to January 2021.
Results:
A total of 23 neonates underwent 57 sessions of RCA-CRRT. Their mean age was 10.1 ± 6.9 days and mean weight was 3.0 ± 0.7 kg (range, 0.95–4 kg). The mean filter life was 31.54 ± 19.58 h (range, 3.3–72.5 h). Compared to pretreatment values, the total-to-ionized calcium ratio (T/iCa) on RCA-CRRT increased (2.00 ± 34 0.36 vs. 2.19 ± 0.40, P = 0.056) as did the incidence of T/iCa levels >2.5 (11.4 vs. 14.3, P = 0.477), albeit not significantly. Using a post-treatment T/iCa threshold of 2.5, we divided all the cases into citrate accumulation (CA) and non-CA (NCA) groups. Compared with the NCA group, the CA group had significantly higher body weight (3.64 ± 0.32 kg vs. 2.95 ± 0.41 kg, P = 0.033) and significantly lower blood flow rate per body weight ml/kg/min (3.08 ± 0.08 vs. 4.07 ± 0.71, P = 0.027); however, there was no significant difference between the two groups in terms of age, corrected gestational age, the PRISM-III score, and biochemical tests.
Conclusion:
RCA-CRRT is safe and effective for neonates. After appropriate adjustments of the RCA-CRRT parameters, the incidence of CA was not higher in neonates than in children or adults, and CA was not found to be significantly correlated with age or corrected gestational age.
Introduction
Continuous renal replacement therapy (CRRT) increases the chances of survival of critically ill patients by preventing fluid overload, correcting the acid–base status and electrolyte imbalance, and allowing optimal use of parenteral nutrition (1). With advances in neonatal care and CRRT technology, CRRT is being increasingly applied in NICU for treating acute kidney injury (AKI) (2, 3), multiorgan dysfunction, and metabolic diseases, such as hyperammonemia (4). Neonatal CRRT is the most technically demanding CRRT of any age group. The major challenges associated with neonatal CRRT use are related to the establishment of vascular access and the management of anticoagulation and hemodynamics. The current reports on neonatal CRRT mainly concern systemic heparin anticoagulation (5) and no heparin anticoagulation (6, 7), and RCA has only been reported in individual cases (8–10). With CRRT, the risk of clotting is higher in neonates than in children and adults due to the slow blood flow. In addition, critically ill neonates often have coagulation disorders, and premature neonates are prone to intracranial hemorrhage and pulmonary hemorrhage. Therefore, anticoagulation during CRRT in neonates is a major clinical challenge. The biggest advantage of RCA is that it is fully anticoagulated in vitro and has no effect on coagulation in vivo. RCA was recommended by KDIGO in 2012 as the preferred anticoagulation modality for CRRT in cases/patients without contraindications to citrate anticoagulation (11). In recent years, studies on RCA-CRRT have been increasingly reported in children (12, 13) but are still rare in neonates. This could be attributed to neonatologists’ concerns about the immaturity of the neonatal liver, which affects neonates’ ability to metabolize citrate and leads to RCA-related complications. In addition, neonatal RCA-CRRT regimens may differ from adults and even children, such as in calcium supplementation, because newborns are at greater risk of hypocalcemia due to immature sarcoplasmic reticulum development. Although neonatal RCA-CRRT has also been reported individually in the form of co-reports in small infants, to our knowledge, RCA-CRRT has not been reported exclusively in neonates (14). Therefore, such reports cannot reflect the differences between neonates and children or adults undergoing RCA-CRRT.
The study aims to share our experience with RCA-CRRT in neonates, especially concerning the technical and practical aspects of such treatment.
Methods
Patients
We conducted a retrospective observational study of newborns (age <28 days, irrespective of gestational age) treated with RCA-CRRT in the pediatric intensive care unit at the Children's Hospital of Chongqing Medical University from September 2015 to January 2021. The study was approved by the ethical committee of Children's Hospital of Chongqing Medical University (approval no.: 2022.120).
CRRT procedures
The PlasautoΣ blood purification device (Asahi Kasei Kuraray Medical, Japan) was used for all patients with AEF-03 filters (filter capacity: 26 ml) and CRRT-CSGNL1 tubes (capacity: 47 ml). Vascular access for CRRT was a 5F double-lumen catheter (ARROW: CS-14502) inserted through the right or left internal jugular vein, or one 5F double-lumen catheter each through the right or left internal jugular vein, or a 20–22G indent needle through the brachial or femoral artery. All CRRT procedures were performed as continuous veno-venous hemodiafiltration. After routine priming the CRRT cycle with heparin saline and saline, 0.25 U red blood cell suspension and 5 g of 20% albumin stock solution were given to prime the CRRT cycle. Calcium-free treatment solutions for dialysis and replacement were self-configured with the following concentrations: ionized sodium, 113 mmol/L; iCa2+, 1.6 mmol/L; Mg2+, 0.797 mmol/L; Cl−, 118 mmol/L; and anhydrous glucose, 10.6 mmol/L. The citrate sodium anticoagulant (4%; approval no.: H20058913; Sichuan Nightingale Biological, China) was infused into the extracorporeal blood circulation using an infusion pump (Optima PT, Fresenius SE & Co. KGaA, Germany) through a T-junction connected at the primer of the artery port. Calcium gluconate (10%) was infused into the extracorporeal blood circulation by an Agilia infusion micropump (Fresenius SE & Co. KGaA, Germany) through a T-junction connected at the end of the venous port.
The initial parameters were set as shown in Table 1. First, we adjusted the flow rate of 4% sodium citrate (CiFR) to reach the target concentration of ionized calcium in vitro of 0.2–0.4 mmol/L. If ionized calcium increased in vitro, we increased CiFR, and vice versa. Then, we adjusted the flow rate of 10% calcium gluconate (CaFR) to reach the target ionized calcium in vivo concentration of 1.0–1.35 mmol/L. If ionized calcium increased in vivo, we decreased CaFR, and vice versa. Finally, we adjusted sodium bicarbonate 5% rate (SBFR) according to blood gas analysis to reach a target bicarbonate concentration of 22–27 mmol/L.
Table 1
| Initial parameter reference | Initial parameters | Final parameters | P value | |
|---|---|---|---|---|
| BFR/BW, ml/kg/min | 3–5 | 3.82 ± 0.86 | 3.92 ± 0.87 | 0.078 |
| CiFR/(60*BFR) | 1.5 | 1.41 ± 0.17 | 1.48 ± 0.17 | 0.014 |
| Moles of citrate per Molers of citrate per CiFR/BW, mmol/kg/h | 0.61–1.02 | 0.70 (0.62, 0.86) | 0.74 (0.64, 0.94) | 0.110 |
| CaFR/(60*BFR) | 0.1 | 0.15 ± 0.06 | 0.17 ± 0.07 | 0.014 |
| DFR/BW, ml/kg/h | 25 | 21.74 (16.67, 30.30) | 25.86 (18.63, 34.48) | 0.302 |
| FFR/BW, ml/kg/h | 35 | 30.30 (23.33, 33.65) | 30.43 (24.19, 36.52) | 0.166 |
| (DFR + FFR)/BW, ml/kg/h | 60 | 52.17 (40.00, 64.04) | 59.57 (45.00, 69.27) | 0.236 |
| SBFR/(DFR + FFR) | 0.01 | 0.011 (0.008, 0.017) | 0.012 (0.000, 0.020) | 0.643 |
Comparison of initial and final parameters.
BFR, blood flow rate, ml/min; BW, body weight, kg; CiFR, flow rate of 4% sodium citrate, ml/h; CaFR, flow rate of 10% calcium gluconate, ml/h; DFR, dialysate flow rate, ml/h; FFR, filtrate flow rate, ml/h; SBFR, 5% sodium bicarbonate flow rate, ml/h. Considering a newborn weighing 3 kg as an example, the initial parameters were set as BFR = 10 ml/min, CiFR = 15 ml/h, CaFR = 1 ml/h, DFR = 75 ml/h, FFR = 105 ml/h, and SBFR = 1.8 ml/h.
Blood gas analysis (ABL90 FLEX Analyzer), both in vivo and in vitro, was conducted every 30 min after starting the treatment until the in vitro target of ionized calcium was achieved, and then, it was routinely performed every 4–6 h. Biochemical indicators and electrolytes were checked every 12–24 h.
Data collection and definition
Data on the CRRT operating parameters, filter lifespan, reasons for CRRT, and laboratory results were collected from medical records. We included cases wherein the treatment administered was CRRT anticoagulated with RCA in newborns (age, <28 days). We excluded cases wherein the treatment administered was CRRT anticoagulated with heparin or CRRT without anticoagulation. The indications of CRRT were: (i) Neonatal AKI with fluid overload, or electrolyte disorder or internal environment improved not obviously after regular treatment (15); (ii) Hyperaminoemia. blood ammonia level >150 μmol/L with rapidly deteriorating neurological status, coma, or cerebral oedema after regular treatment (16). Data characteristics are shown in Figure 1.
Figure 1
Citrate accumulation (CA) was defined as the ratio of total-to-ionized calcium (T/iCa) being >2.5. Patients were divided into CA and non-CA (NCA) groups according to whether their condition was complicated with CA after treatment. Hypocalcemia was defined as iCa being <0.9 mmol/L, whereas hypercalcemia was defined as iCa being >1.35 mmol/L. Hyponatremia was defined as sodium ion concentration being <135 mmol/L, whereas hypernatremia was defined as sodium ion concentration being >145 mmol/L. Metabolic acidosis was defined as bicarbonate levels being <22 mmol/L, whereas metabolic alkalosis was defined as bicarbonate levels being >27 mmol/L.
Statistical analysis
Enumeration data were analyzed using the chi-squared test. Normally distributed continuous variables were presented as mean ± standard deviation and compared using the t test or expressed as median (first and third quartile) and compared using the Mann–Whitney U test, as appropriate. Statistical analyses were performed with IBM SPSS version 21 software. A P-value of <0.05 was considered statistically significant.
Results
Patients’ characteristics
In total, 23 newborns (14 males) who collectively underwent 57 sessions of RCA-CRRT were included. At the time of CRRT initiation, the mean age was 10.1 ± 6.9 days (corrected for gestational age, 268 ± 24 days), and the mean body weight was 3.0 ± 0.7 kg (range, 0.95–4 kg). There were 25 (43.8%) sessions with prothrombin time >17 s and 46 (82.5%) sessions with activated partial thromboplastin time >47 s before treatment. Nine children died in the hospital, and the death was not directly attributed to CRRT. The demographic and clinical characteristics of the patients are described in Table 2.
Table 2
| Parameter | Value |
|---|---|
| N | 23 |
| Sessions, n | 57 |
| Age, days | 10.1 ± 6.9 |
| Correct gestational age, days | 268.3 ± 24.7 |
| Body weight, kg | 3.0 ± 0.7 |
| Sex, male | 14 |
| PRISM III score | 26.27 ± 0.64 |
| In-hospital mortality | 9 (39.1%) |
| Cause of death | |
|  Low cardiac output syndrome | 2 |
|  Severe hypoxic ischemic encephalopathy | 2 |
|  Necrotizing enterocolitis | 1 |
|  Persistent pulmonary hypertension | 1 |
|  Severe congenital diaphragmatic hernia | 1 |
|  Severe hyperammonemia | 2 |
| 28-day mortality | 11 (47.8%) |
| Primary diagnosis | |
|  Cardiac disease | 10 |
|  Sepsis | 2 |
|  Metabolic disease | 3 |
|  Renal | 2 |
|  Primary pulmonary | 1 |
|  Intestinal disease | 3 |
|  Others | 1 |
| Bleeding risk before CRRT | |
|  Postoperative | 13/23 (56.5%) |
|  Intracranial hemorrhage | 4/23 (17.4%) |
|  Prothrombin time >17 s | 25/57 (43.8%) |
|  Activated partial thromboplastin time >46 s | 46/57 (82.5%) |
|  Platelets <100 × 109 | 32/57 (56.1%) |
| Filter lifespan, h | 31.54 ± 19.58 |
|  <24 h | 22 |
|  Reasons for filter lifespan <24 h | |
|   Ionized calcium in vitro >0.4 mmol/L | 11 |
|   Catheter malfunction | 10 |
|   Hypotension | 1 |
|  >48 h | 12 |
| Reasons for disconnection | |
|  Catheter malfunction | 8 |
|  Discontinuation of treatment or death | 11 |
|  Clotting | 36 |
|  72 h filter change | 2 |
Clinical characteristics of patients.
Data are presented as mean ± SD (range) or percentage. Correct gestational age: gestational age + days since birth.
Effectiveness
The mean filter lifespan was 31.54 ± 19.58 h (range, 3.3–72.5 h). The mean ionized calcium in vitro during RCA-CRRT was 0.37 ± 0.08 mmol/L. A total of 207 measurements of ionized calcium in vitro were obtained, of which 128 (61.8%) were <0.4 mmol/L. The distribution of filter lifespan and reasons for disconnection are shown in Table 2. After the treatment, creatinine levels decreased significantly but urea nitrogen and lactic acid levels did not (Table 3).
Table 3
| Before RCA-CRRT (n = 57) | After RCA-CRRT (n = 51) | P value | |
|---|---|---|---|
| Urea nitrogen, mmol/L | 8.82 ± 6.11 | 8.80 ± 8.18 | 0.987 |
| Creatinine, mmol/L | 92.96 ± 51.58 | 73.90 ± 27.20 | 0.032 |
| Lactic acid, mmol/L | 2.40 (1.05, 4.50) | 1.80 (0.90, 3.00) | 0.087 |
| pH | 7.37 ± 0.14 | 7.44 ± 0.11 | 0.001 |
|  <7.35 | 22 | 10 | 0.025 |
|  >7.45 | 19 | 22 | 0.198 |
| Bicarbonate, mmol/L | 25.70 ± 6.27 | 29.66 ± 4.95 | 0.000 |
|  <22 mmol/L | 15 | 4 | 0.010 |
|  >27 mmol/L | 23 | 37 | 0.001 |
| Ionized calcium in vivo, mmol/L | 1.18 ± 0.14 | 1.17 ± 0.13 | 0.692 |
|  <0.9 mmol/L | 3 | 1 | 0.352 |
|  >1.35 mmol/L | 4 | 4 | 0.578 |
| T/iCa | 2.00 ± 0.36 | 2.19 ± 0.40 | 0.056 |
|  >2.5 | 5/44 (11.4%) | 5/35 (14.3%) | 0.477 |
| Ionized sodium, mmol/L | 139.74 ± 6.38 | 139.85 ± 6.08 | 0.928 |
|  <135 mmol/L | 13 | 8 | 0.246 |
|  >145 mmol/L | 10 | 6 | 0.285 |
Comparison of blood gas analysis and biochemical indices before and after RCA-CRRT.
T/iCa, the ratio of total calcium to ionic calcium.
Complications
After treatment, pH value, bicarbonate levels, and the incidence of bicarbonate levels being >27 mmol/L increased significantly, and the incidence of pH being <7.35 and bicarbonate levels being <22 mmol/L decreased significantly. No significant difference was noted in the concentration of ionized calcium in vivo, concentration of ionized sodium, the incidence of pH being >7.45, hypernatremia, hyponatremia, hypercalcemia, and hypocalcemia. Both T/iCa and the incidence of T/iCa being >2.5 increased, but the increase was not significant (Table 3).
Influencing factors of CA
Thirty-five T/iCa measurements were obtained after treatment, and 22 measurements could not be obtained because of reasons such as child death or abandonment during CRRT. After CRRT, there were five sessions with T/iCa > 2.5 (CA group) and 30 sessions with T/iCa < 2.5 (NCA group). The molers of citrate per CiFR/BW was lower in the CA group than in the NCA group, but the difference was not significant. The weight was significantly higher in the CA group than in the NCA group, and the BFR/BW was significantly smaller in the CA group than in the NCA group. However, the two groups showed no significant difference in terms of age, corrected gestational age, PRISM-III score, or biochemical test findings, such as prothrombin time, activated partial thromboplastin time, total bilirubin, direct bilirubin, aspartate aminotransferase, alanine transaminase, GGT, lactic acid, and terminal parameters, such as CiFR/BFR and CaFR/BFR (QD + QF)/BW. The details in this regard are shown in Table 4.
Table 4
| Parameter | NCA group | CA group | P value |
|---|---|---|---|
| N | 30 | 5 | |
| Before RCA-CRRT | |||
|  PRISM III score | 25.00 (24.75, 28.00) | 27.00 (26.00, 28.00) | 0.242 |
|  Age, days | 8.80 ± 4.76 | 7.40 ± 2.51 | 0.646 |
|  Correct gestational age, days | 274.4 ± 18.2 | 281.0 ± 2.2 | 0.454 |
|  Weight, kg | 2.95 ± 0.41 | 3.64 ± 0.32 | 0.033 |
| Before RCA-CRRT | |||
|  Prothrombin time, s | 11.12 ± 8.81 | 12.76 ± 7.54 | 0.355 |
|  Activated partial thromboplastin time, s | 69.50 ± 28.92 | 114.60 ± 62.17 | 0.166 |
|  Total bilirubin, μmol/L | 137.83 ± 73.44 | 134.98 ± 45.51 | 0.904 |
|  Direct bilirubin, μmol/L | 4.55 (0.00, 14.58) | 3.50 (1.45, 21.05) | 0.535 |
|  Aspartate aminotransferase, IU/L | 55.00 (28.75, 138.00) | 48.00 (39.90, 97.50) | 0.906 |
|  Alanine transaminase, IU/L | 27.78 ± 10.14 | 28.00 ± 9.01 | 0.976 |
|  Glutamyl transpeptidase, IU/L | 80.72 ± 55.09 | 26.26 ± 2.80 | 0.095 |
|  Lactic acid, mmol/L | 3.44 ± 2.10 | 4.91 ± 3.20 | 0.461 |
| Final parameters | |||
|  BFR/BW, ml/min | 4.07 ± 0.71 | 3.08 ± 0.08 | 0.027 |
|  CiFR/(60*BFR) | 1.45 ± 0.14 | 1.37 ± 0.12 | 0.287 |
|  CaFR/(60*BFR) | 0.117 ± 0.024 | 0.140 ± 0.029 | 0.200 |
|  (DFR + FFR)/BW, ml/h | 55.1 ± 12.4 | 48.5 ± 11.4 | 0.551 |
|  Molers of citrate per CiFR/BW, mmol/kg/h | 0.774 ± 0.185 | 0.637 ± 0.071 | 0.117 |
| CRRT duration, h | 25.8 ± 12.7 | 21.1 ± 6.1 | 0.575 |
Comparison of CA and NCA group after RCA-CRRT.
CA, T/iCa > 2.5 at the end of RCA-CRRT; NCA, T/iCa < 2.5 at the end of RCA-CRRT; BFR, blood flow rate, ml/min; BW, body weight, kg; CiFR, flow rate of 4% sodium citrate, ml/h; CaFR, flow rate of 10% calcium gluconate, ml/h; DFR, dialysate flow rate, ml/h; FFR, filtrate flow rate, ml/h.
Parameter adjustment
CiFR/BFR and CaFR/BFR were the only treatment settings to be significantly altered compared with initial treatment parameters. The details are shown in Table 1.
Discussion
In this study, we analyzed the performance of RCA-CRRT in critically ill newborns. We found RCA to be safe and effective for CRRT anticoagulation in newborns. The risk of CA in neonates with RCA-CRRT was not significantly related to age and corrected gestational age, and the citrate metabolism capacity of neonates may not be worse than that of children or adults.
The requirements for CRRT anticoagulation are more stringent in neonates than in children and adults. It is well known that a slower blood flow rate is associated with a higher risk of clotting. Therefore, effective anticoagulation in vitro is extremely important to prolong filter life. In addition, neonatal CRRT is often complicated by high risk of bleeding. First, critically ill neonates are often associated with high risk of hemorrhage, which typically manifests as coagulation disorders, and premature infants are particularly vulnerable to hemorrhage due to immaturity of the brain, lung, and other organs. In this study, of the 57 sessions of RCA-CRRT, there were 25 (43.8%) sessions with prothrombin time >17 s and 46 (82.5%) sessions with activated partial thromboplastin time >47 s before treatment. At the first RCA-CRRT, the corrected gestational age of 6 (26.1%) out of 23 neonates was still <37 weeks. Second, due to the low blood volume of neonates, the pre-filling with red cell suspension and albumin before CRRT will significantly reduce the concentration of coagulation factors, and after CRRT, the extracorporeal blood is often not returned to the body, resulting in direct loss of coagulation factors. The blood is not returned because the minimum blood pump velocity of 1 ml/min is still too high, which may lead to cardiac deterioration or even cardiac failure in newborns. The average weight of newborns in the current study was 3 kg, and the extracorporeal circulation volume was about 1/3–1/4 of the newborns’ total blood volume. In addition, thrombocytopenia was observed in the CRRT sessions, which increases the risk of bleeding (17). The decrease in platelet count can be attributed to platelet activation and degranulation from exposure to the roller pump in the CRRT machine and by attaching with the microbubbles or dialysate (15). A hemofilter could contribute to thrombocytopenia during CRRT by either destruction or retention of platelets during passage (18). Therefore, a protocol with an exact anticoagulation effect in vitro and without affecting their own coagulation function in vivo is more suitable for neonatal CRRT.
RCA can maintain effective anticoagulation during CRRT in newborns. Ionized calcium in vitro concentration of 0.2–0.4 mmol/L was typically used as the anticoagulation target during RCA-CRRT (19–22). In this study, during RCA-CRRT, the mean ionized calcium in vitro concentration was 0.37 ± 0.08 mmol/L, and the ionized calcium in vitro concentration was <0.4 mmol/L in 61.8% sessions. The mean filter lifespan was 31.54 ± 19.58 h (range, 3.3–71.5 h), which was comparable to the filter lifespan of other neonatal CRRTs anticoagulated with heparin (14–51.1 h) (23, 24).
Excessive ionized calcium in vitro and poor catheter function are major factors limiting the filter lifespan of neonatal RCA-CRRT. In this study, there were 22 sessions with a filter lifespan of <24 h, of which 11 (50%) sessions had ionized calcium in vitro >0.4 mmol/L, 10 (45.5%) sessions were considered to be caused by poor catheter function, and the remaining 1 (4.5%) session was related to hypotension.
The CA risk associated with RCA-CRRT in neonates is not higher than it is in children or adults and is not significantly related to the gestational age. Notably, CA is the most concerning complication of neonatal RCA-CRRT, and neonatologists often worry that the liver and other organs of newborns are immature, which will lead to insufficient citrate metabolism. In this study, there was no significant difference in the incidence of CA before and after the treatment. After RCA-CRRT, the incidence of CA was 14.3%, which was significantly lower than that reported by Persic et al. in their study on neonatal and infant RCA-CRRT (25%) (14). Compared with the NCA group, in the CA group, the body weight was significantly higher and the BFR/BW value was significantly lower, and the molers of citrate per CiFR/BW value was lower but without statistical significance. However, this does not suggest that children with higher body weights and smaller molers of citrate per CiFR/BW values are more likely to develop CA. The significant difference in body weight is more likely to be related to the bias caused by the small number of CA cases. Conversely, in the CA group, to reduce the risk or degree of CA, we further reduced BFR/BW, thereby resulting in a smaller molers of citrate per CiFR/BW value. In other words, as CA had already occurred, we further reduced CiFR to reduce the degree of CA or even avoid CA. In addition, there was no significant difference in age (days), corrected gestational age, molers of citrate per CiFR/BW, prothrombin time, activated partial thromboplastin time, aspartate aminotransferase, alanine transaminase, lactic acid, and other indicators between the CA and NCA group. This indicates that the occurrence of CA in neonatal RCA-CRRT may not be associated with whether the birth was preterm or not and the degree of preterm birth. The average molers of citrate per CiFR/BW in this group was 0.79 mmol/kg/h, which was similar to the minimum predicted accumulation concentration reported by Persic et al. (14) (0.78–1.7 mmol/L).
Limitation
The current study has some limitations. Given its retrospective design, some data are missing. In addition, the sample size is small and may be subject to statistical bias; however, to our knowledge, this is the largest sample size in a neonatal RCA-CRRT study to date.
Conclusion
RCA is safe and effective for neonatal CRRT anticoagulation. Neonates with RCA-CRRT were not at a significantly higher risk of developing CA than children or adults. The risk of CA showed no significant correlation with gestational age or corrected gestational age.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by The study was approved by the ethical committee of Children’s Hospital of Chongqing Medical University, File NO.: 2022.120. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Author contributions
KB and CL contributed to the study design. HH and HD oversaw data collection. FX and HD contributed to analysis. All authors contributed to the article and approved the submitted version.
Funding
Program for Youth Innovation in Future Medicine from Chongqing Medical University: Basic and Clinical Study of Critical Illness in Children (2021-W0111).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
SelewskiDTCharltonJRJettonJGGuilletRMhannaMJAskenaziDJet alNeonatal acute kidney injury. Pediatrics. (2015) 136:e463–73. 10.1542/peds.2014-3819
2.
KaddourahAGoldsteinSL. Renal replacement therapy in neonates. Clin Perinatol. (2014) 41:517–27. 10.1016/j.clp.2014.05.003
3.
SohnYBPaikKHChoHYKimSJParkSWKimESet alContinuous renal replacement therapy in neonates weighing less than 3 kg. Korean J Pediatr. (2012) 55:286. 10.3345/kjp.2012.55.8.286
4.
SpinaleJMLaskinBLSondheimerNSwartzSJGoldsteinSL. High-dose continuous renal replacement therapy for neonatal hyperammonemia. Pediatr Nephrol. (2013) 28:983–6. 10.1007/s00467-013-2441-8
5.
Diane MokTYTsengM-HChiangM-CLinJ-LChuSMHsuJ-Fet alRenal replacement therapy in the neonatal intensive care unit. Pediatr Neonatol. (2018) 59:474–80. 10.1016/j.pedneo.2017.11.015
6.
GarzottoFVidalERicciZPaglialongaFGiordanoMLaforgiaNet alContinuous kidney replacement therapy in critically ill neonates and infants: a retrospective analysis of clinical results with a dedicated device. Pediatr Nephrol. (2020) 35:1699–705. 10.1007/s00467-020-04562-y
7.
KimJYLeeYChoH. Optimal prescriptions of continuous renal replacement therapy in neonates with hyperammonemia. Blood Purif. (2019) 47:16–22. 10.1159/000492660
8.
SoltysiakJWarzywodaAKocińskiBOstalska-NowickaDBenedykASilska-DittmarMet alCitrate anticoagulation for continuous renal replacement therapy in small children. Pediatr Nephrol. (2014) 29:469–75. 10.1007/s00467-013-2690-6
9.
Raymakers-JanssenPAMALilienMvan KesselIAVeldhoenESWösten-van AsperenRMvan GestelJPJ. Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children. Pediatr Nephrol. (2017) 32:1971–8. 10.1007/s00467-017-3694-4
10.
DavisTKNeumayrTGeileKDoctorAHmeilP. Citrate anticoagulation during continuous renal replacement therapy in pediatric critical care. Pediatr Crit Care Med. (2014) 15:471–85. 10.1097/PCC.0000000000000148
11.
LameireNKellumJA. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care. (2013) 17(1):205. 10.1186/cc11455
12.
KreuzerMBonzelK-EBuscherROffnerGEhrichJHHPapeL. Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding. Nephrol Dial Transplant. (2010) 25:3337–42. 10.1093/ndt/gfq225
13.
LietJ-MAllain-LaunayEGaillard-LeRouxBBarrièreFChenouardADejodeJ-Met alRegional citrate anticoagulation for pediatric CRRT using integrated citrate software and physiological sodium concentration solutions. Pediatr Nephrol. (2014) 29:1625–31. 10.1007/s00467-014-2770-2
14.
PersicVVajdic TrampuzBMedvedBPavcnikMPonikvarRGubensekJ. Regional citrate anticoagulation for continuous renal replacement therapy in newborns and infants: focus on citrate accumulation. Artif Organs. (2020) 44:497–503. 10.1111/aor.13619
15.
GodinMMurrayPMehtaRL. Clinical approach to the patient with AKI and sepsis. Semin Nephrol. (2015) 35(1):12–22. 10.1016/j.semnephrol.2015.01.003
16.
RainaRBedoyanJKLichter-KoneckiUJouvetPPiccaSMewNAet alConsensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. Nat Rev Nephrol. (2020) 16(8):471–82. 10.1038/s41581-020-0267-8
17.
NishimiSSugawaraHOnoderaCToyaYFurukawaHKonishiYet alComplications during continuous renal replacement therapy in critically ill neonates. Blood Purif. (2019) 47:74–80. 10.1159/000496654
18.
SutherlandSMZappitelliMAlexanderSRChuaANBrophyPDBunchmanTEet alFluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis. (2010) 55:316–25. 10.1053/j.ajkd.2009.10.048
19.
CortinaGMcRaeRChilettiRButtW. The effect of patient- and treatment-related factors on circuit lifespan during continuous renal replacement therapy in critically ill children. Pediatr Crit Care Med. (2020) 21(6):578–85. 10.1097/PCC.0000000000002305
20.
LeviMOpalSM. Coagulation abnormalities in critically ill patients. Critical Care. (2006) 10(4):222. 10.1186/cc4975
21.
SıkGDemirbugaAAnnayevACitakA. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill children. Int J Artif Organs. (2020) 43(4):234–41. 10.1177/0391398819893382
22.
Raymakers-JanssenPAMALilienMvan KesselIAVeldhoenESAsperenRMW-vvan GestelJPJet alCitrate versus heparin anticoagulation in continuous renal replacement therapy in small children. Pediatr Nephrol. (2017). 32:1971–78. 10.1007/s00467-017-3694-4
23.
GarzottoFVidalERicciZPaglialongaFGiordanoMLaforgiaNet alContinuous kidney replacement therapy in critically ill neonates and infants: a retrospective analysis of clinical results with a dedicated device. Pediatr Nephrol. (2020) 35:1699–705. 10.1007/s00467-020-04562-y
24.
LeeSTChoH. Fluid overload and outcomes in neonates receiving continuous renal replacement therapy. Pediatr Nephrol. (2016) 31:2145–52. 10.1007/s00467-016-3363-z
Summary
Keywords
citrate accumulation, continuous renal replacement therapy, newborns, regional citrate anticoagulation, critically ill
Citation
Huang H, Deng X, Bai K, Liu C, Xu F and Dang H (2023) Regional citrate anticoagulation for continuous renal replacement therapy in newborns. Front. Pediatr. 11:1089849. doi: 10.3389/fped.2023.1089849
Received
10 November 2022
Accepted
16 February 2023
Published
08 March 2023
Volume
11 - 2023
Edited by
Enrico Vidal, University of Udine, Italy
Reviewed by
Michiel J. S. Oosterveld, Amsterdam University Medical Center, Netherlands Raphael Schild, University Medical Center Hamburg-Eppendorf, Germany
Updates
Copyright
© 2023 Huang, Deng, Bai, Liu, Xu and Dang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ke Bai 480114@hospital.cqmu.edu.cn
These authors share first authorship
Specialty Section: This article was submitted to Pediatric Nephrology, a section of the journal Frontiers in Pediatrics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.